NEW YORK – A new partnership involving researchers at Stanford University, Kailos Genetics, and digital health firm Doc.ai could result in new models for using pharmacogenomics data and artificial intelligence to predict the best treatments for patients with epilepsy.
Led by Robert Fisher, director of the Stanford Epilepsy Center, the Epilepsy Digital Health Trial commenced last month with the aim of combining personal information, pharmacogenomics data, and machine-learning tools to select the best anti-seizure medication for patients.